Dexrazoxane as a Cardioprotectant in Children Receiving Anthracyclines
نویسندگان
چکیده
منابع مشابه
Clinical status and optimal use of the cardioprotectant, dexrazoxane.
There are many challenges facing those involved in chemotherapy drug development. In addition to identification of new agents, clinical investigators must address questions regarding the optimal methods of administration of established agents so as to maximize efficacy and minimize toxicity. Treatment toxicity affects not only morbidity and mortality but also issues of dose intensity, quality o...
متن کاملClinical Status and Optimal Use of the Cardioprotectant, Dexrazoxane
The anthracycline antitumor antibiotics are important chemotherapeutic agents for the treatment of leukemias, lymphomas, breast cancer, myeloma, small-cell lung cancer, sarcomas, bladder cancer, and pediatric solid tumors. However, the clinical usefulness of the anthracycline antibiotics is limited by their cardiac toxicity, and clinicians confront a clinical dilemma as they balance the efficac...
متن کاملUse of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
GUIDELINE QUESTIONS 1) Should dexrazoxane be used routinely in patients with advanced or metastatic cancer who are at risk of developing cardio toxicity when receiving chemotherapy containing doxorubicin or epirubicin? 2) Do the available data support the use of dexrazoxane when anthracyclines are being used in the adjuvant setting for patients at risk of developing cardiotoxicity? OBJECTIVE ...
متن کاملDexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: analysis of a national cohort of patients in the Pediatric Health Information Systems database.
BACKGROUND Acute lymphoblastic (ALL) and myeloid leukemia (AML) account for approximately 26% of pediatric cancers. Anthracyclines are widely used to treat these leukemias, but dosing is limited by cardiotoxicity. Data support the efficacy of dexrazoxane as a cardioprotectant in children; however, dexrazoxane use in children is not universally accepted due to concerns about toxicity, impact on ...
متن کاملTamoxifen as an antioxidant and cardioprotectant.
Tamoxifen is widely used in the treatment of breast cancer and has been proposed as a prophylactic agent in this disease. Tamoxifen is an effective antioxidant and protects membranes and low-density lipoprotein (LDL) particles against oxidative damage. This antioxidant action is shared by endogenous and synthetic oestrogens. The ability of tamoxifen to protect LDL particles against the oxidativ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Oncologist
سال: 2010
ISSN: 1083-7159,1549-490X
DOI: 10.1634/theoncologist.2010-0162